Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and ...

(NASDAQ:NVAX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company ...

Shares of Novavax Inc. NVAX shed 3.02% to $9.32 Friday, on what proved to be an all-around rough trading session for the ...

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant ...

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

Novavax, Inc. (NASDAQ:NVAX – Get Free Report)’s share price traded down 5.8% during mid-day trading on Monday .The stock traded as low as $7.62 and last traded at $7.80. 1,894,875 shares ...

The stock's fall snapped a five-day winning streak.

This makes it worthwhile to examine what the stock has in store. Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...